Enzalutamide: A novel anti-androgen with prolonged survival rate in CRPC patients

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 10, 2013, Pages 1475-1486

  Dhingra, Richa ^a   Sharma, Tina ^a   Singh, Sukhminder ^a   Sharma, Shivani ^a   Tomar, Prince ^a   Malhotra, Manav ^a   Bhardwaj, T R ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Androgen deprivation therapy (ADT); Anti androgen; Castration resistant prostate cancer (CRPC); Enzalutamide

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; ENZALUTAMIDE; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANOREXIA; ARTICLE; BACKACHE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DNA BINDING; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; GENE EXPRESSION; GLUCOSE INTOLERANCE; HEADACHE; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; LIGAND BINDING; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL PAIN; NAUSEA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SEIZURE; SIDE EFFECT; SIGNAL TRANSDUCTION; WEIGHT GAIN;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; SURVIVAL RATE;

EID: 84881529561     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/13895575113139990003     Document Type: Article

References (62)

1. Feldman, B.J.; Feldman, D. The development of androgen-independent prostate cancer. Nat Rev Cancer., 2001, 1, 34-45.
2. Grossmann, M.E.; Huang, H.; Tindall, D.J. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst., 2001, 93, 1687-1697.
3. Pienta, K.J.; Bradley, D. Mechanisms underlying the development of androgen independent prostate cancer. Clin Cancer Res., 2006, 12, 1665-1671.
4. Scher, H.I.; Sawyers, C.L. Biology of progressive castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol., 2005, 23, 8253-8261.
5. Boyle, P.; Ferlay, J. Cancer incidence and mortality in Europe 2004. Ann Oncol., 2005, 16, 481-488.
6. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Smigal, C.; Thun, M.J. Cancer., 2008, 58, 71-96.
7. Parkin, D.M.; Bray, F.I.; Devesa, S.S. Cancer burden in the year 2000: the global picture. Eur J Cancer., 2001, 37, 4-66.
8. Huggins, C.; Hodges, C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J. Clin., 1972, 22, 232-240.
9. Attard, G.; Richards, J.; Bono, J.S. New strategies in metastatic prostate cancer: targeting the androgen receptor signalling pathway. Clin Cancer Res., 2011, 17, 1649-1657.
10. Scher, H.I.; Buchanan, G.; Gerald, W.; Butler, L.M.; Tilley, W.D. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endoc Rel Cancer., 2004, 11, 459-476.
11. Holzbeierlein, J.; Lal, P.; LaTulippe, E.; Smith, A.; Satagopan, J.; Zhang, L.; Ryan, C.; Smith, S.; Scher, H.; Scardino, P.; Reuter, V.; Gerald, W.L. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol., 2004, 164, 217-227.
12. Visakorpi, T.; Hyytinen, E.; Koivisto, P.; Tanner, M.; Keinänen, R.; Palmberg, C.; Palotie, A.; Tammela, T.; Isola, J.; Kallioniemi, O.P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet., 1995, 9, 401-406.
13. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet., 2000, 355, 1491-1498.
14. Taplin, ME.; Manola, J.; Oh, WK.; Kantoff, PW.; Bubley, GJ.; Smith, M. A phase II study of mifepristone (RU-486) in castrationresistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int., 2008, 101, 1084-1089.
15. Labrie, C.; Cusan, L.; Plante, M.; Lapointe, S.; Labrie, F. Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer. J Steroid Biochem., 1987, 28, 379-84.
16. Dijkman, GA.; Janknegt, RA.; De Reijke, TM.; Debruyne, FM. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. J urol., 1997, 158, 160-163.
17. Schellhammer, PF.; Sharifi, R.; Block, NL.; Soloway, MS.; Venner, PM.; Patterson, AL. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urol., 1997, 50, 330-336.
18. Tran, C.; Ouk, S.; Clegg, N.J.; Chen, Y.; Watson, P.A.; Arora, V.; Wongvipat, J.; Smith-Jones, P.M.; Yoo, D.; Kwon, A.; Wasielewska, T.; Welsbie, D.; Chen, C.D.; Higano, C.S.; Beer, T.M.; Hung, D.T.; Scher, H.I.; Jung, M.E.; Sawyers, C.L. Development of a second generation antiandrogen for treatment of advanced prostate cancer. Science., 2009, 324, 787-790.
19. Scher, HI; Beer, TM, Higano, CS, Anand, A, Taplin, ME, Efstathiou, E, Rathkopf, D, Shelkey, J, Yu, EY, Alumkal, J, Hung, D, Hirmand, M, Seely, L, Morris, MJ, Danila, DC, Humm, J, Larson, S, Fleisher, M, Sawyers, CL, Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials, Consortium. Antitumor activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet., 2010, 376, 1437-1446.
20. Culig, Z.; Hoffmann, J.; Erdel, M.; Eder, I.E.; Hobisch, A.; Hittmair, A.; Bartsch, G.; Utermann, G.; Schneider, M.R.; Parczyk, K.; Klocker, H. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumor progression in a new model system. Br J Cancer., 1999, 81, 242-251.
21. Scher, H.I.; Kelly, W.K. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol., 1993, 11, 1566-1572.
22. Jung, M.E.; Ouk, S.; Yoo, D.; Sawyers, C.L.; Chen, C.; Tran, C.; Wongvipat, J. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem., 2010, 53, 2779-2796.
23. Brinkmann, A.O. Androgen Physiology: Receptor and metabolic disorders in Receptor and Metabolic Disorders; Ed.; PCRI Insights, 2011; Vol. 15, pp. 3-5.
24. Nacusi, L.P.; Tindall, D.J. Androgen receptor abnormalities in castration-recurrent prostate cancer. Exp Rev Endocrinol Metab., 2009, 4, 417-422.
25. Nishiyama, T.; Hashimoto, Y.; Takahashi, K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res., 2004, 10, 7121-7126.
26. Chang, K.H.; Li, R.; Papari-Zareei, M.; Watumull, L.; Zhao, Y.D.; Auchus, R.J.; Sharifi, N. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci., 2011, 108, 13728-13733.
27. Gregory, C.W.; Johnson, R.T.; Mohler, J.L.; French, FS.; Wilson, EM. Androgenreceptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res., 2001, 61, 2892-2898.
28. Koivisto, P.; Kononen, J.; Palmberg, C.; Tammela, T.; Hyytinen, E.; Isola, J.; Trapman, J. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res., 1997, 57, 314-319.
29. Bubendorf, L.; Kononen, J.; Koivisto, P.; Schraml, P.; Moch, H. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res., 1999, 59, 803-806.
30. Kawata, H.; Ishikura, N.; Watanabe, M.; Nishimoto, A.; Tsunenari, T.; Aoki, Y. Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate., 2010, 70, 745-754.
31. Wang, L.G.; Ossowski, L.; Ferrari, A.C. Androgen receptor level controlled by a suppressor complex lost in an androgen independent prostate cancer cell line. Oncogene., 2004, 23, 5175-5184.
32. Kraus, S.; Gioeli, D.; Vomastek, T.; Gordon, V.; Weber, M.J. Receptor for activated C kinase 1(RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. Cancer Res., 2006, 66, 11047-11054.
33. Litvinov, I.V.; De Marzo, A.M.; Isaacs, J.T. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling. J Clin Endocrinol Metab., 2003, 88, 2972-2982.
34. Foster, W.R.; Car, B.D.; Shi, H.; Levesque, P.C.; Obermeier, M.T.; Gan, J.; Arezzo, J.C.; Powlin, S.S.; Dinchuk, J.E.; Balog, A.; Salvati, M.E.; Attar, R.M.; Gottardis, M.M. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate., 2011, 71, 480-488.
35. Visakorpi, T.; Hyytinen, E.; Koivisto, P.; Tanner, M.; Keinänen, R.; Palmberg, C.; Palotie, A.; Tammela, T.; Isola, J.; Kallioniemi, O.P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet., 1995, 9, 401-406.
36. Belikov, S.; Astrand, C.; Holmqvist, PH.; Wrange, O. Chromatin-mediated restriction of nuclear factor 1/CTF binding in a repressed and hormone-activated promoter in vivo. Mol. Cell Biol., 2004, 24, 3036-3047.
37. Belikov, S.; Holmqvist, PH.; Astrand, C.; Wrange, O. Nuclear factor 1 and octamer transcription factor 1 binding preset the chromatin structure of the mouse mammary tumor virus promoter for hormone induction. J. Biol. Chem., 2004, 279, 49857-49867.
38. Belikov, S.; Astrand, C.; Wrange, O. FoxA1 binding directs chromatin structure and the functional response of a glucocorticoid receptor-regulated promoter. Mol. Cell Biol., 2009, 29, 5413-5425.
39. John, S.; Sabo, P.J.; Johnson, T.A.; Sung, M.H.; Biddie, S.C.; Lightman, S.L.; Voss, T.C.; Davis, S.R.; Meltzer, P.S.; Stamatoyannopoulos, J.A., Hager, G.L., 2008. Interaction of the glucocorticoid receptor with the chromatin landscape. Mol. Cell. 29, 611-624.
40. John, S.; Sabo, P.J.; Thurman, R.E.; Sung, M.H.; Biddie, S.C.; Johnson, T.A.; Hager, G.L.; Stamatoyannopoulos, J.A. Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat. Genet., 2011, 43, 264-268.
41. Siersbaek, R., Nielsen, R., John, S., Sung, M.H., Baek, S., Loft, A., Hager, G.L., Mandrup, S., 2011. Extensive chromatin remodelling and establishment of transcription factor 'hotspots' during early adipogenesis. EMBO J. 30, 1459-1472.
42. Gerhardt, J.; Montani, M.; Wild, P.; Beer, M.; Huber, F.; Hermanns, T.; Muntener, M.; Kristiansen, G. FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer. Am. J. Pathol., 2012, 180, 848-861.
43. Grasso, CS.; Wu, YM.; Robinson, DR.; Cao, X.; Dhanasekaran, SM.; Khan, AP.; Quist, MJ.; Jing, X.; Lonigro, RJ.; Brenner, JC.; Asangani, IA.; Ateeq, B.; Chun, SY.; Siddiqui, J.; Sam, L.; Anstett, M.; Mehra, R.; Prensner, JR.; Palanisamy, N.; Ryslik, GA.; Vandin, F.; Raphael, BJ.; Kunju, LP.; Rhodes, DR.; Pienta, KJ.; Chinnaiyan, AM.; Tomlins, SA. The mutational landscape of lethal castration resistant prostate cancer. Nature., 2012, 487, 239-243.
44. Liu W, et al. Neoplasia 2008;10:897. [PubMed: 18670647]
45. Heinlein, C.A.; Chang, C. Androgen receptor in prostate cancer. Endocr Rev., 2004, 25, 276-308.
46. Migliaccio, A.; Castoria, G.; Di Domenico, M.; Falco, A.; Bilancio, A.; Lombardi, M.; Barone, M.V.; Ametrano, D.; Zannini, M.S.; Abbondanza, C.; Auricchio, F. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J., 2000, 19, 5406-5417.
47. Kousteni, S.; Bellido, T.; Plotkin, L.I.; O'Brien, C.A.; Bodenner, D.L.; Han, L.; Han, K.; DiGregorio, G.B.; Katzenellenbogen, J.A.; Katzenellenbogen, B.S.; Roberson, P.K.; Weinstein, R.S.; Jilka, R.L.; Manolagas, S.C. Nongenotropic, sex-nonspecific signalling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell., 2001, 104, 719-730.
48. Castoria, G.; Lombardi, M.; Barone, M.V.; Bilancio, A.; Di Domenico, M.; Bottero, D.; Vitale, F.; Migliaccio, A.; Auricchio, F. Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor action. J Cell Biol., 2003, 161, 547-556.
49. Grossmann, ME.; Huang, H.; Tindall, D.J. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst., 2001, 93, 1687-1697.
50. Michael, E.; Jung, S.O.; Dongwon, Y.; Charles, L.; Sawyers, C.C.; Chris, T.; John, W. Structure-Activity Relationship for Thiohydantoin Androgen Receptor Antagonists for Castration-Resistant Prostate Cancer (CRPC). J Med Chem., 2010, 53, 2779-2796.
51. Jung, M.E.; Ouk, S.; Sawyers, C.L.; Chen, C.D.; Welsbie, D. Methods and Materials for Assessing Prostate Cancer Therapies and Compounds. U.S. Patent Appl. 10, 590, 445, Feburary 23, 2005.
52. Sawyers, C.L.; Jung, M.E.; Chen, C.D.; Ouk, S.; Welsbie, D. Novel Androgen Receptor Inhibitors with Minimal Agonistic Activities. U.S. Patent Appl. 60, 680, 835, Janurary 28, 2002.
53. Scher, H.I.; Beer, T.M.; Higano, C.S.; Anand, A.; Taplin, M.E.; Efstathiou, E.; Rathkopf, D.; Shelkey, J.; Yu, E.Y.; Alumkal, J.; Hung, D.; Hirmand, M.; Seely, L.; Morris, M.J.; Humm, J.; Larson, S.; Fleisher, M.; Sawyers, C.L. Antitumor activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet., 2010, 375, 1437-1446.
54. Scher, H.I.; Halabi, S.; Tannock, I.; Morris, M.; Sternberg, C.N.; Carducci, M.A.; Eisenberger, M.A.; Higano, C.; Bubley, G.J.; Dreicer, R.; Petrylak, D.; Kantoff, P.; Basch, E.; Kelly, W.K.; Figg, W.D.; Small, E.J.; Beer, T.M.; Wilding, G.; Martin, A.; Hussain, M. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol., 2008, 26, 1148-1159.
55. Scher, H.I.; Warren, M.; Heller, G. The Association between Measures of Progression and Survival in Castrate-Metastatic Prostate Cancer. Clin Cancer Res., 2007, 13, 1488-1492.
56. Basch, E.M.; Somerfield, M.R.; Beer, T.M.; Carducci, M.A.; Higano, C.S.; Hussain, M.H.; Scher, H.I. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol., 2007, 25, 5313-5318.
57. Scher, HI.; Warren, M.; Heller, G. The Association Between Measures of Progression and Survival in Castrate-Metastatic Prostate Cancer. Clin Cancer Res., 2007, 13, 1488-1492.
58. Oken, M.M.; Creech, R.H.; Tormey, D.C.; Horton, J.; Davis, T.E.; McFadden, E.T.; Carbone, P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol., 1982, 5, 649-655
59. Atkinson, T.M.; Rosenfeld, B.D.; Sit, L.; Mendoza, T.R.; Fruscione, M.; Lavene, D.; Shaw, M.; Li, Y.; Hay, J.; Cleeland, C.S.; Scher, H.I.; Breitbart, W.S.; Basch, E. Using confirmatory factor analysis to evaluate constructs validity of the Brief Pain Inventory (BPI). J Pain Symp Man., 2011, 41, 558-565.
60. Saad, F.; Gleason, D.M.; Murray, R.; Tchekmedyian, S.; Venner, P.; Lacombe, L.; Chin, J.L.; Vinholes, J.J.; Goas, J.A.; Chen, B. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Cancer Inst., 2002, 94, 1458-1468.
61. Grossmann, M.; Zajac, J.D. Management of side effects of androgen deprivation therapy. Endocrinol Metab Clin North Am., 2011, 40, 655-671.
62. Kumar, R.J.; Barqawi, A.; Crawford, E.D. Adverse events associated with hormonal therapy for prostate cancer. Rev Urol., 2005, 5, 37-43.